Most read psoriasis articles of 2022

FDA approvals led this year’s most read psoriasis articles on Healio.

The approval of Vtama for the treatment of plaque psoriasis emerged as the most read psoriasis article of 2022. Articles about an FDA-issued complete response letter to UCB and the efficacy of spesolimab in treating pustular psoriasis were also popular with readers.

Here are Healio’s top 10 psoriasis articles of 2022.

FDA approves Vtama for topical psoriasis treatment

In May, Dermavant Sciences announced the FDA approval of Vtama (tapinarof) 1% cream for the treatment of plaque psoriasis in patients with mild, moderate or severe disease. The aryl hydrocarbon receptor agonist was the first topical drug approved for the treatment of psoriasis in more than 25 years and the only nonsteroidal drug approved for this indication. Read more.

FDA approves roflumilast cream for plaque psoriasis

The FDA approved Zoryve cream for the treatment of plaque psoriasis, Arcutis announced in July. Zoryve (roflumilast cream 0.3%) is a nonsteroid, phosphodiesterase-4 inhibitor that is used as a once-daily topical treatment for psoriasis. It is the first PDE4 inhibitor approved for this indication. Read more.

FDA approves Sotyktu for psoriasis

In September, Bristol Myers Squibb’s deucravacitinib, an oral, selective allosteric tyrosine kinase 2 inhibitor, was approved by the FDA for the treatment of moderate to severe plaque psoriasis. Read more.

FDA issues complete response letter for bimekizumab for plaque psoriasis

The FDA issued a complete response letter to UCB in May regarding the biologics license application for bimekizumab. The letter stated that the application could not be approved until preapproval inspection observations were resolved. Read more.

Long-term treatment with Vtama cream safe, effective for plaque psoriasis

In July, Healio reported on results of a long-term efficacy study showing that treatment with Vtama for plaque psoriasis provided improvement beyond 12 weeks with nearly half of patients achieving full clearance. Read more.

Spesolimab may offer hope for patients with generalized pustular psoriasis

The humanized anti-interleukin-36 receptor monoclonal antibody spesolimab demonstrated strong efficacy results with an attractive safety profile in patients with generalized pustular psoriasis, Healio reported in January. Read more.

Guselkumab ranks high in psoriasis clearance among psoriatic arthritis treatments

In a meta-analysis presented at Maui Derm for Dermatologists, guselkumab showed better efficacy in psoriasis skin clearance than most psoriatic arthritis treatments. The review included 33 randomized controlled trials, with 31 trials being placebo-controlled up to 24 weeks and two trials being head-to-head studies. Read more.

Probiotics improve psoriasis disease activity, quality of life after 8 weeks

An 8-week course of daily probiotics was associated with improvements in a number of psoriasis disease parameters, including quality of life, according to an article published this summer. Read more.

FDA approves Spevigo for generalized pustular psoriasis

In September, the FDA approved Spevigo for the treatment of generalized pustular psoriasis. This is the first investigational drug to target the interleukin-36 pathway for generalized pustular psoriasis flares. Read more.

Vunakizumab shows early efficacy in plaque psoriasis

Vunakizumab showed efficacy in treating moderate to severe plaque psoriasis at all dose levels, with a 240 mg dose showing the best clinical response, according to a phase 2 trial in January. The novel humanized monoclonal immunoglobulin targets IL-17A. Read more.